Abstract
Many prolonged-release preparations are designed so that a certain fraction is immediately available for absorption upon administration, while the remainder becomes available for absorption at an effectively constant rate. Recently, a number of prolonged-release propoxyphene hydrochloride formulations have been designed to dissolve in this manner in vitro.We employed a pharmacokinetic model, product dissolution data, and historical plasma concentration data to predict the plasma propoxyphene concentrations which might result from a particular mix and thus minimize the number of formulations requiring evaluation in subjects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
